

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS
FOR THE SIX MONTHS PERIOD ENDED 30 JUNE 2023 AND
LIMITED REVIEW REPORT

(Convenience translation of the independent auditors' review report and consolidated financial statements originally issued in Turkish)

(CONVENIENCE TRANSLATION OF THE REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION ORIGINALLY ISSUED IN TURKISH)

REPORT ON REVIEW OF CONSOLIDATED INTERIM FINANCIAL INFORMATION

To the General Assembly of Deva Holding A.Ş.

Introduction

We have reviewed the accompanying consolidated statement of financial position of Deva Holding A.Ş. (“the Company”) and its subsidiaries (together will be referred as “the Group”) as of 30 June 2023 and the related consolidated statements of profit or loss and other comprehensive income, changes in equity and cash flows for the six-month period then ended, and a summary of significant accounting policies and other explanatory notes. Group management is responsible for the preparation and fair presentation of this consolidated interim financial information in accordance with Turkish Financial Reporting Standards. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

Scope of Review

We conducted our review in accordance with Independent Auditing Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”. A review of consolidated interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Independent Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information does not present fairly, in all material respects, the financial position of Deva Holding A.Ş. and its subsidiaries as of 30 June 2023, and of their financial performance and their cash flows for the six-month period then ended in accordance with Turkish Financial Reporting Standards.

Additional paragraph for convenience translation to English

In the accompanying interim consolidated financial statements, the accounting principles described in Note 2 (defined as Turkish Accounting Standards/Turkish Financial Reporting Standards) differ from International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board with respect to the application of inflation accounting. Accordingly, the accompanying interim consolidated financial statements are not intended to present the financial position and results of operations in accordance with IFRS.

DRT BAĞIMSIZ DENETİM VE SERBEST MUHASEBECİ MALİ MÜŞAVİRLİK A.Ş.
Member of **DELOITTE TOUCHE TOHMATSU LIMITED**

Zere Gaye Şentürk
Partner

İstanbul, 18 August 2023

Index	Page
Consolidated statement of financial position	1 - 2
Consolidated statement of profit or loss	3
Consolidated statement of comprehensive income	4
Consolidated statement of changes in equity	5
Consolidated statement of cash flows	6 - 7
Notes to the consolidated financial statements	8 80

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 30 JUNE 2023**

(Amounts expressed in Turkish Liras)

		Current Year Reviewed 30 June 2023	Prior Year Audited 31 December 2022
	Footnote References		
ASSETS			
Current Assets		7.517.320.384	5.464.758.250
Cash and cash equivalents	4	751.418.258	601.243.499
Financial investments	5	1.427.240.703	734.615.057
Trade receivables		2.680.958.317	1.765.455.139
<i>Due from related parties</i>	7	<i>154.689.101</i>	<i>86.024.749</i>
<i>Due from third parties</i>	8	<i>2.526.269.216</i>	<i>1.679.430.390</i>
Other receivables	9	9.787.144	3.870.442
Derivative instruments	32	13.782.384	-
Inventories	10	2.419.008.356	2.008.634.018
Prepaid expenses	11	156.976.623	227.964.505
Assets relating to current tax	12	410.286	775.568
Other current assets	21	57.738.313	122.200.022
Non-Current Assets		3.583.358.850	3.159.542.430
Financial investments	5	287.270.780	432.107.872
Property, plant and equipment	13	1.838.652.352	1.648.592.969
Right of use assets	14	431.177.772	102.555.594
Intangible assets		775.475.932	577.298.639
<i>Goodwill</i>	16	<i>1.782.731</i>	<i>1.782.731</i>
<i>Other intangible assets</i>	15	<i>773.693.201</i>	<i>575.515.908</i>
Prepaid expenses	11	146.096.882	293.146.147
Deferred tax assets	29	104.685.132	105.841.209
TOTAL ASSETS		11.100.679.234	8.624.300.680

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS OF 30 JUNE 2023**

(Amounts expressed in Turkish Liras)

		Current Year Reviewed 30 June 2023	Prior Year Audited 31 December 2022
LIABILITIES			
Current Liabilities		5.252.422.991	4.023.286.288
Short term financial liabilities		3.476.432.632	2.457.258.522
<i>Bank borrowings</i>	6	2.904.389.882	2.307.258.522
<i>Other short-term debts</i>	6	572.042.750	150.000.000
Current portion of long term financial liabilities		432.173.271	436.287.651
<i>Bank borrowings</i>	6	377.424.858	324.767.319
<i>Lease liabilities</i>	6	54.748.413	9.959.963
<i>Debt bond in issue</i>	6	-	101.560.369
Trade payables		703.927.116	713.706.921
<i>Due to related parties</i>	7	52.082.301	22.515.635
<i>Due to third parties</i>	8	651.844.815	691.191.286
Payables relating to the benefits provided to employees	20	71.020.404	46.065.560
Other payables		15.740.241	2.083.719
<i>Other trade payables</i>	9	15.740.241	2.083.719
Government grants and incentives	17	2.141.260	2.246.055
Deferred revenue	11	44.692.432	25.043.179
Current tax payable	29	88.931.409	1.660.332
Short term provisions		405.435.673	328.206.900
<i>Provisions for benefits provided to employees</i>	20	171.111.887	126.453.597
<i>Other provisions</i>	18	234.323.786	201.753.303
Other current liabilities	21	11.928.553	10.727.449
Non-Current Liabilities		658.513.300	664.190.412
Long term financial liabilities		515.574.935	505.282.590
<i>Bank borrowings</i>	6	117.874.866	239.444.412
<i>Lease liabilities</i>	6	397.700.069	265.838.178
Government grants and incentives	17	45.872.493	48.997.401
Deferred revenue	11	23.895.121	13.547.187
Long term provisions		73.170.751	96.363.234
<i>Provisions for benefits provided to employees</i>	20	73.170.751	96.363.234
EQUITY		5.189.742.943	3.936.823.980
Equity attributable to equity holders of the parent		5.189.742.943	3.936.823.980
Paid-in capital	22	200.019.288	200.019.288
Inflation adjustment to share capital	22	140.080.696	140.080.696
Treasury shares (-)	22	(28.847)	(28.847)
Premium in excess of par	22	2.870.803	2.870.803
Other comprehensive expense not to be reclassified to profit or loss		(6.921.152)	(6.921.152)
<i>Actuarial loss arising from defined benefit plans</i>		(6.921.152)	(6.921.152)
Other comprehensive expense to be reclassified to profit or loss		151.821.987	52.075.076
<i>Currency translation reserve</i>		151.821.987	52.075.076
Restricted reserves appropriated from profit	22	150.864.955	150.864.955
Accumulated profit	22	3.203.121.345	2.037.638.940
Profit for the period		1.347.913.868	1.360.224.221
TOTAL LIABILITIES AND EQUITY		11.100.679.234	8.624.300.680

The accompanying notes form an integral part of these consolidated financial statements.

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS
FOR THE PERIOD ENDED 30 JUNE 2023**

(Amounts expressed in Turkish Liras)

		Current Year Reviewed 1 January – 30 June 2023	Prior Year Reviewed 1 January – 30 June 2022	Current Year Unaudited 1 April – 30 June 2023	Prior Year Unaudited 1 April – 30 June 2022
Revenue	23	3.900.801.739	1.903.978.095	1.897.454.199	1.019.932.911
Cost of revenue (-)	23	(1.646.552.253)	(906.504.940)	(808.315.736)	(498.061.308)
GROSS PROFIT		2.254.249.486	997.473.155	1.089.138.463	521.871.603
Marketing, sales and distribution expenses (-)	24	(473.983.507)	(238.310.762)	(235.407.802)	(137.923.084)
General administration expenses (-)	24	(339.338.764)	(150.880.551)	(197.628.275)	(80.600.730)
Research and development expenses (-)	24	(77.315.436)	(80.742.471)	(34.624.463)	(29.783.487)
Other operating income	26	176.001.825	275.852.307	117.469.983	153.937.812
Other operating expenses (-)	26	(20.775.223)	(37.727.641)	(14.399.037)	(30.809.983)
OPERATING PROFIT		1.518.838.381	765.664.037	724.548.869	396.692.131
Investment income	27	441.170.799	43.386.557	389.548.060	39.176.581
PROFIT BEFORE FINANCE EXPENSES		1.960.009.180	809.050.594	1.114.096.929	435.868.712
Finance expenses (-)	28	(443.172.469)	(204.787.678)	(225.425.178)	(122.646.268)
PROFIT BEFORE TAXATION		1.516.836.711	604.262.916	888.671.751	313.222.444
Tax (expense) / income		(168.922.843)	54.827.408	14.405.705	(5.239.460)
Current tax expense (-)	29	(167.766.766)	(3.144.531)	(10.475.442)	(1.020.565)
Deferred tax (expense) / income	29	(1.156.077)	57.971.939	24.881.147	(4.218.895)
Net profit for the period		1.347.913.868	659.090.324	903.077.456	307.982.984
Distribution of profit for the period					
Equity holders of the parent		1.347.913.868	659.090.324	903.077.456	307.982.984
		1.347.913.868	659.090.324	903.077.456	307.982.984
Earning per share	30	0,0674	0,0330	0,0451	0,0154

The accompanying notes form an integral part of these consolidated financial statements.

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF OTHER COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 30 JUNE 2023**

(Amounts expressed in Turkish Liras)

	Current Year Reviewed 1 January – 30 June 2023	Prior Year Reviewed 1 January – 30 June 2022	Current Year Unaudited 1 April – 30 June 2023	Prior Year Unaudited 1 April – 30 June 2022
Net profit for the period	1.347.913.868	659.090.324	903.077.456	307.982.984
OTHER COMPREHENSIVE INCOME / (LOSS)				
Items not to be reclassified subsequently to profit or loss				
Actuarial (loss) / gain arising from defined benefit plans	20	-	-	-
Tax effect other comprehensive income not to be reclassified to profit or loss	29	-	-	-
Items that may be reclassified subsequently to profit or loss				
Change in foreign currency translation reserve	99.746.911	9.519.514	73.303.838	1.868.015
OTHER COMPREHENSIVE INCOME	99.746.911	9.519.514	73.303.838	1.868.015
TOTAL COMPREHENSIVE INCOME	1.447.660.779	668.609.838	976.381.294	309.850.999
Total comprehensive income attributable to:	1.447.660.779	668.609.838	976.381.294	309.850.999
Equity holders of the parent	1.447.660.779	668.609.838	976.381.294	309.850.999

The accompanying notes form an integral part of these consolidated financial statements.

(Convenience translation of
originally issued in Turkish)

consolidated financial statements

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 30 JUNE 2023**

(Amounts expressed in TRY thousands)

Notes	Paid in capital	Inflation adjustment to share capital	Treasury shares (-)	Premium in excess of par	Other comprehensive income/(expense) not to be reclassified to profit or loss	Other comprehensive income/(expense) to be reclassified to profit or loss	Accumulated profit				Total equity attributable to equity holders of the parent	Total shareholder's equity
					Actuarial loss arising from defined benefit plans	Currency translation reserve	Restricted reserves appropriated from profit	Accumulated profit	Net profit for the period			
Balance as of 1 January 2022	22	200.019.288	140.080.696	(28.847)	2.870.803	(5.252.460)	27.972.911	150.864.955	1.041.162.023	1.170.087.476	2.727.776.845	2.727.776.845
Transfer to retained earnings		-	-	-	-	-	-	-	1.170.087.476	(1.170.087.476)	-	-
Profit shares *		-	-	-	-	-	-	-	(173.610.559)	-	(173.610.559)	(173.610.559)
Total comprehensive income		-	-	-	-	-	9.519.514	-	-	659.090.324	668.609.838	668.609.838
<i>Currency translation reserve</i>		-	-	-	-	-	<i>9.519.514</i>	-	-	-	<i>9.519.514</i>	<i>9.519.514</i>
<i>Profit for the period</i>		-	-	-	-	-	-	-	-	<i>659.090.324</i>	<i>659.090.324</i>	<i>659.090.324</i>
Balance as of 30 June 2022	22	200.019.288	140.080.696	(28.847)	2.870.803	(5.252.460)	37.492.425	150.864.955	2.037.638.940	659.090.324	3.222.776.124	3.222.776.124
Balance as of 1 January 2023	22	200.019.288	140.080.696	(28.847)	2.870.803	(6.921.152)	52.075.076	150.864.955	2.037.638.940	1.360.224.221	3.936.823.980	3.936.823.980
Transfer to retained earnings		-	-	-	-	-	-	-	1.360.224.221	(1.360.224.221)	-	-
Profit shares *		-	-	-	-	-	-	-	(194.741.816)	-	(194.741.816)	(194.741.816)
Total comprehensive income		-	-	-	-	-	99.746.911	-	-	1.347.913.868	1.447.660.779	1.447.660.779
<i>Currency translation reserve</i>		-	-	-	-	-	<i>99.746.911</i>	-	-	-	<i>99.746.911</i>	<i>99.746.911</i>
<i>Profit for the period</i>		-	-	-	-	-	-	-	-	<i>1.347.913.868</i>	<i>1.347.913.868</i>	<i>1.347.913.868</i>
Balance as of 30 June 2023	22	200.019.288	140.080.696	(28.847)	2.870.803	(6.921.152)	151.821.987	150.864.955	3.203.121.345	1.347.913.868	5.189.742.943	5.189.742.943

(*) At the 2022 Ordinary General Assembly Meeting held on April 28, 2023, it was decided that; the shareholders representing TRY 200.019.288 of the capital for 2022, to be paid 15% gross; 13,5% net dividend amounting to a total of TRY 194.741.816 (gross TRY/krs 0,15, net TRY/krs 0,1350 per a share in the amount of TRY 1) depending on their legal status; this dividends to be paid in cash as of May 8, 2023.

The accompanying notes form an integral part of these consolidated financial statements.

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 30 JUNE 2023**

		Current Year Reviewed 1 January – 30 June 2023	Prior Year Reviewed 1 January – 30 June 2022
CASH FLOWS FROM OPERATING ACTIVITIES		692.309.363	325.746.517
Profit for the period		1.347.913.868	659.090.324
Adjustments to Reconcile Profit (Loss)		693.310.753	498.646.950
Adjustments for depreciation and amortisation expense	13,14,15, 23,25	77.755.988	47.020.036
Adjustments for Impairment Loss (Reversal of Impairment Loss)		157.615.006	168.874.041
Adjustments for Impairment Loss (Reversal of Impairment Loss) of Receivables	8,9	-	(54.376)
Adjustments for Impairment Loss (Reversal of Impairment Loss) of Inventories	10	27.848.751	52.126.316
Adjustments for Impairment Loss (Reversal of Impairment Loss) of Other Intangible Assets	15	129.766.255	116.802.101
Adjustments for Provisions		317.766.396	215.184.772
Adjustments for (Reversal of) Provisions Related with Employee Benefits	20	120.141.194	38.636.696
Adjustments for (Reversal of) Lawsuit and/or Penalty Provisions	18	10.204.835	7.535.722
Adjustments for (Reversal of) Other Provisions	18	187.420.367	169.012.354
Adjustments for Interest (Income) Expenses		357.132.114	182.406.703
Adjustments for interest income	26	(37.380.443)	(16.086.154)
Adjustments for interest expense	28	394.512.557	198.492.857
Adjustments for Fair Value (Income) Expenses:		(273.830.570)	(268.790)
Adjustments for Fair Value (Gains) Losses of Financial Investments	27	(260.048.186)	(268.790)
Increase (Decrease) in Derivatives	32	(13.782.384)	-
Adjustments for Tax (Income) Expenses		168.922.843	(54.827.408)
Other Adjustments for Non-Cash Items		(104.779.180)	(45.103.009)
Adjustments for Losses (Gains) on Disposal of Non-Current Assets		(12.104.654)	(9.128.982)
Adjustments for Losses (Gains) Arised From Sale of Tangible Assets	27	(12.104.654)	(9.128.982)
Other adjustments for Which Cash Effects are Investing or Financing Cash Flow		11.720.066	(2.610.811)
Other Adjustments to Reconcile Profit (Loss)		(6.887.256)	(2.899.602)
Changes in Working Capital		(1.216.929.232)	(811.469.064)
Adjustments for Decrease (Increase) in Trade Accounts Receivable		(910.575.273)	(441.131.425)
Increase (Decrease) in Trade Accounts Receivables from Related Parties	7	(68.664.352)	(12.979.508)
Increase (Decrease) in Trade Accounts Receivables from Other Parties		(841.910.921)	(428.151.917)
Adjustments for Decrease (Increase) in Other Receivables Related with Operations		(5.916.702)	(964.457)
Decrease (Increase) in Other Third Party Receivables Related with Operations	9	(5.916.702)	(964.457)
Adjustments for Decrease (Increase) in Inventories		(405.162.730)	(482.185.953)
Decrease (Increase) in Prepaid Expenses		70.987.882	28.243.383
Adjustments for Increase (Decrease) in Trade Accounts Payable		(9.779.805)	72.361.920
Increase (Decrease) in Trade Accounts Payables to Related Parties	8	29.566.666	15.346.772
Increase (Decrease) in Trade Accounts Payables to Unrelated Parties	8	(39.346.471)	57.015.148
Increase (Decrease) in Employee Benefit Liabilities		24.954.844	2.167.705
Adjustments for Increase (Decrease) in Other Operating Payables		13.656.522	895.000
Increase (Decrease) in Other Operating Payables to Other Parties	9	13.656.522	895.000
Increase (Decrease) in Deferred Income	11	29.997.187	(4.692.955)
Other Adjustments for Other Increase (Decrease) in Working Capital		(25.091.157)	13.837.718
Decrease (Increase) in Other Assets Related with Operations	12,21	64.826.991	(56.517.747)
Increase (Decrease) in Other Payables Related with Operations		(89.918.148)	70.355.465
Cash Flows from (used in) Operations		824.295.389	346.268.210
Interest received	4,26	33.565.826	15.874.573
Payments Related with Provisions for Employee Benefits	20	(105.276.313)	(11.322.392)

86 Tm0 g0 G{()25(1)38(1)38(1)9(3)38(2)38(2)W* nBTf125(e)0 1 486.68 41.31-)-37(r)25()19(E)73(m)86(p)-37W* n0 g0 G(3)-37(4)-71f

The accompanying notes form an integral part of these consolidated financial statements.

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

**CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIOD ENDED 30 JUNE 2023**

(Amounts expressed in Turkish)

		Current Year Reviewed 1 January – 30 June 2023	Prior Year Reviewed 1 January – 30 June 2022
CASH FLOWS FROM INVESTING ACTIVITIES		(814.439.232)	(1.150.993.023)
Proceeds from Sales of Property, Plant, Equipment and Intangible Assets		12.104.654	9.128.982
Proceeds from Sales of Property, Plant and Equipment	13,27	12.104.654	9.128.982
Purchase of Property, Plant, Equipment and Intangible Assets		(687.474.584)	(450.668.001)
Purchase of Property, Plant and Equipment	13	(266.255.275)	(198.317.274)
Purchase of Intangible Assets (*)	6,14,15,28	(421.219.309)	(252.350.727)
Cash Outflows Arising From Debt Instruments	5,27	(287.740.368)	(569.468.825)
Cash Advances and Loans Made		147.049.265	(141.709.893)
Other Cash Advances and Loans Made to Other Parties	11	147.049.265	(141.709.893)
Proceeds from Government Grants	17	1.621.801	1.724.714
CASH FLOWS FROM FINANCING ACTIVITIES		168.743.100	604.542.395
Proceeds from Loans		2.117.591.699	2.075.853.448
Proceeds from Borrowings	6	1.767.591.699	2.075.853.448
Other short-term debts	6	350.000.000	-
Debt Repayments		(1.350.895.425)	(1.104.984.075)
Cash outflows regarding repayments of borrowings	6	(1.249.335.056)	(974.984.075)
Cash outflows regarding payments of bonds issued	6	(101.560.369)	(130.000.000)
Cash outflows related with payments of lease liabilities	6	(78.410.292)	(28.286.733)
Cash outflows regarding payments of dividend	22	(194.741.816)	(173.610.559)
Interest paid	6,28	(324.801.066)	(164.429.686)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS BEFORE EFFECT OF EXCHANGE RATE CHANGES		46.613.231	(220.704.111)
Effect of exchange rate changes on cash and cash equivalents		99.746.911	9.519.514
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		146.360.142	(211.184.597)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	4	600.671.319	1.310.128.102
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	4	747.031.461	1.098.943.505

(*) Amount of TRY 112.884.960 advances given for right of use asset purchases are included in the cash outflows item of the purchase of intangible assets.

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2023

(Amounts expressed in TRY)

1. ORGANIZATION AND OPERATIONS OF THE GROUP

Deva Holding A.Ş. is operating in the pharmaceutical sector. The Company was incorporated on 22 September 1958. The Company's principal activity is manufacturing and marketing of human pharmaceuticals. The registered office address and its principal place of business are as follows:

No: 1

The average number of employees working in the Group for the period ended 30 June 2023 is 2.942 (31 December 2022: 2.844).

Eastpharma S.A.R.L. is the main shareholder of the Company. Eastpharma S.A.R.L. was founded in Luxembourg in 2006 and is fully owned by Eastpharma Ltd., which was incorporated in Bermuda in 2006. Eastpharma S.A.R.L. acquired 52,000 shares of Deva Holding A.Ş. in 2006. Subsequent to that date EP SARL increased its shareholdings and as of 30 June 2023, it owns 82,2% of the shares of Deva (31 December 2022: 82,2%). The ultimate shareholders of Eastpharma S.A.R.L. are the funds controlled by Global Equities Management S.A.

The shares of the Company have been traded on Borsa Istanbul since 24 March 1986.

As of 30 June 2023, the Company consists of 20.001.928.778 shares with an amount of TRY 0,01 for each share (31 December 2022: 20.001.928.778). The Company's capital structure is as follows (Note 22):

<u>Name</u>	<u>(%)</u>	<u>30 June 2023</u>	<u>(%)</u>	<u>31 December 2022</u>
Eastpharma S.A.R.L.	82,2	164.424.760	82,2	164.424.760
Shares held by public	17,8	35.594.528	17,8	35.594.528
Nominal capital	100,0	200.019.288	100,0	200.019.288
Inflation adjustment to share capital		140.080.696		140.080.696
Treasury shares (-)		(28.847)		(28.847)
Adjusted share capital		<u>340.071.137</u>		<u>340.071.137</u>

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2023

(Amounts expressed in Turkish Liras)

1. ORGANIZATION AND OPERATIONS OF THE GROUP (cont'd)

Subsidiaries

As of 30 June 2023 and 31 December 2022, the details of the subsidiaries in terms of ownership and principal business activities are as follows:

<u>Company</u>	<u>Effective Ownership (%)</u>		<u>Line of activity</u>
	<u>30 June 2023</u>	<u>31 December 2022</u>	
Devatis Ltd	100	100	Distribution and sale of human and veterinary pharmaceuticals in New Zealand and Australia
Devatis Inc	100	100	Distribution and sale of human and veterinary pharmaceuticals in USA
Devatis GmbH	100	100	Distribution and sale of human and veterinary pharmaceuticals in Germany
Devatis PTY Ltd (*)	100	100	Distribution and sale of human and veterinary pharmaceuticals in Australia
Devatis A.G(*)	100	100	Distribution and sale of human and veterinary pharmaceuticals in Switzerland
Devatis de Mexico (*)	100	100	Distribution and sale of human and veterinary pharmaceuticals in Mexico
Devatis Canada Inc. (*)	100	100	Distribution and sale of human and veterinary pharmaceuticals in Canada
Devatis d.o.o Beograd (*)	100	-	Distribution and sale of human and veterinary pharmaceuticals in Serbia

(*) The companies do not have material effect on the consolidated financial statements. Therefore, they are not included in the consolidation.

T operate outside Turkey.

DEVA HOLDİNG A.Ş. AND ITS SUBSIDIARIES

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 JUNE 2023

(Amounts expressed in Turkish Liras (TL))

1. ORGANIZATION AND OPERATIONS OF THE GROUP (cont'd)

Subsidiaries (cont'd)

The Company and its subsidiaries operate in the pharmaceutical industry and are one of the branded generic players in the market. The Group has a wide range product portfolio and a country-wide organized sales force. The Group has 4 production facilities in 4 different locations.

The Group has 214 pharmaceutical molecules in 422 pharmaceutical forms. Of these 7 molecules (in 8 presentation forms) are manufactured and marketed by using license rights.

As of 30 June 2023 the business segments are production and sale of human pharmaceuticals, veterinary and agricultural products and other.

The human pharmaceuticals segment derives the majority of its revenues from the sale of branded generic and licensed products. Branded generic products are finished pharmaceutical products that Deva produces and sells under its trademark rather than the chemical name of the active pharmaceutical compound. Licensed products are finished pharmaceutical products that the Company produces and sells under licenses from other pharmaceutical companies that hold the rights to the pharmaceutical compound. The business encompasses a wide range of medicines combating diseases in the musculoskeletal, alimentary, metabolism and cardiovascular system and infections. Corporate expenses and assets are included in the human pharmaceuticals segment.

The human pharmaceuticals segment also contains , which mainly derives its revenues from the manufacturing and sale of antibiotic active ingredients to local producers including the Company as well as to foreign pharmaceutical companies. In addition to its manufacturing activities, the Company conducts, at its microbiology laboratories, tests and research on the adaptation of raw materials, selection of micro-organisms, formulation of culture mediums, and executes various test and research fermentations on pilot fermentators.

The income of veterinarians and animal breeders segment is achieved by the sales of 83 pharmaceutical molecules in 124 pharmaceutical forms.

The operations in the other segment include production and sale of cologne products.

Further segment information on the Group operations is presented in Note 3.

Approval of the financial statements

The accompanying financial statements have been approved by the Board of Directors and are authorized for issue on 18 August 2023.

Going Concern

The Group prepared consolidated financial statements in accordance with the going concern assumption.

